Monitoring Infused Treg Cells in vivo to Predict Response, Remission and Relapse

Time: 10:00 am
day: Day Two


  • Cell therapy outcomes in oncology have shown that a durable response is associated with persistence of the infusion product in vivo
  • Adaptive’s highly-sensitive immune sequencing technology characterizes the full TCR repertoire of the infusion product
  • The endogenous TCR can be used to track infused Treg clones in vivo in order to measure persistence and predict response